BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37486225)

  • 1. PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish.
    Hu CB; Huang C; Wang J; Hong Y; Fan DD; Chen Y; Lin AF; Xiang LX; Shao JZ
    J Immunol; 2023 Sep; 211(5):816-835. PubMed ID: 37486225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
    Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTLA-HVEM Checkpoint Axis Regulates Hepatic Homeostasis and Inflammation in a ConA-Induced Hepatitis Model in Zebrafish.
    Shi W; Shao T; Li JY; Fan DD; Lin AF; Xiang LX; Shao JZ
    J Immunol; 2019 Nov; 203(9):2425-2442. PubMed ID: 31562209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
    Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
    Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
    Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8
    Suarez GV; Melucci Ganzarain CDC; Vecchione MB; Trifone CA; Marín Franco JL; Genoula M; Moraña EJ; Balboa L; Quiroga MF
    Sci Rep; 2019 Jan; 9(1):187. PubMed ID: 30655556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.
    Schuster C; Brosi H; Stifter K; Boehm BO; Schirmbeck R
    PLoS One; 2013; 8(8):e71746. PubMed ID: 23977133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
    Raftery MJ; Abdelaziz MO; Hofmann J; Schönrich G
    Front Immunol; 2018; 9():2560. PubMed ID: 30559738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
    Schachtele SJ; Hu S; Sheng WS; Mutnal MB; Lokensgard JR
    Glia; 2014 Oct; 62(10):1582-94. PubMed ID: 24890099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of PD1 and BTLA on the CD8
    Bao Y; Mo JF; Wu JY; Cao CX
    Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
    [No Abstract]   [Full Text] [Related]  

  • 16. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
    Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
    Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
    Yang J; Chen J; Liang H; Yu Y
    Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactive glia promote development of CD103
    Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
    Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow-derived mesenchymal stem cells inhibit CD8
    Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
    Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.